GLP-1s are not started at full strength
The discovery set the stage for a decade of GLP-1 research and development, culminating in newer formulations with greater efficacy and longer dosing intervals
Products are packaged using controlled processes designed to help maintain compound integrity during storage and transit
While current supplies of these novel medications are limited due to production bottlenecks (Lipanovic, 2024), one might expect a decrease in patient out-of-pocket costs due to expansion of production capacity (Novo Nordisk, 2024), increased market competition (Liu et al., 2021, Collins et al., 2024), expanded insurance coverage (Liu and Rome, 2024, Cubanski and Neuman, 2024), and, eventually, expiration of patent protections (Alhiary et al., 2023)
InnoSlim had proactively studied these metabolic pathways, positioning itself perfectly to complement and enhance the mechanisms targeted by prescription GLP-1 medications
Willkommen et al., 2018)
